Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC increased its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 12.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,087,149 shares of the company's stock after buying an additional 655,238 shares during the period. Geode Capital Management LLC owned 1.56% of Recursion Pharmaceuticals worth $41,160,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in RXRX. Decker Retirement Planning Inc. bought a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $26,000. Private Trust Co. NA bought a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at approximately $27,000. GAMMA Investing LLC lifted its position in Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after buying an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after acquiring an additional 1,353 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in Recursion Pharmaceuticals by 220.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company's stock valued at $66,000 after purchasing an additional 6,758 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Stock Up 3.4 %

NASDAQ:RXRX traded up $0.18 during trading hours on Friday, reaching $5.50. The company's stock had a trading volume of 12,710,040 shares, compared to its average volume of 12,004,554. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The company has a market capitalization of $2.21 billion, a P/E ratio of -3.59 and a beta of 1.00. The stock has a 50 day moving average price of $6.66 and a two-hundred day moving average price of $6.80. Recursion Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). The company had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals's revenue for the quarter was down 57.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.42) EPS. Equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on RXRX shares. Morgan Stanley cut their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 8th. KeyCorp lowered their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Finally, Leerink Partners reduced their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research report on Friday, February 28th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $8.20.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.